Consider 505(b)(2) Pathway [Design Issues]

posted by bebac_fan – US, 2018-05-05 17:08 (1557 d 23:25 ago) – Posting: # 18756
Views: 2,555

I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.

In this case, comparative efficacy, rather than BE, will be considered pivotal.

Complete thread:

UA Flag
Activity
 Admin contact
22,292 posts in 4,666 threads, 1,584 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Wednesday 16:34 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5